Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Recruiting 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1NETWORK 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Plasma cell 5

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Multiple Myeloma 39Lymphoma, Large B-Cell, Diffuse 38Burkitt Lymphoma 34Lymphoma 31Leukemia, Myeloid, Acute 31Lymphoma, Non-Hodgkin 29Recurrence 27Breast Neoplasms 27Neoplasms 23Lymphoma, B-Cell 23Myelodysplastic Syndromes 22Leukemia, Lymphocytic, Chronic, B-Cell 22Lymphoma, Follicular 20Hodgkin Disease 18Triple Negative Breast Neoplasms 17Melanoma 17Leukemia 17Ovarian Neoplasms 16Hematologic Neoplasms 15Neuroblastoma 14Lymphoma, Mantle-Cell 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 12Pancreatic Neoplasms 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Leukemia, Biphenotypic, Acute 11Neoplasm Metastasis 10Lymphoma, B-Cell, Marginal Zone 10Leukemia, Myelomonocytic, Chronic 10Sarcoma 9

Interventions

Dexamethasone 7Bortezomib 6Cyclophosphamide 5daratumumab 3Specimen Handling 34-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 3venetoclax 2dexamethasone acetate 2dexamethasone 21-phosphate 2belantamab mafodotin 2auricularum 2X-Rays 2Phantoms, Imaging 2Magnetic Resonance Spectroscopy 2Clinical Protocols 2Calcium Dobesilate 2Biopsy 2ixazomib 1Tissue Banks 1Stem Cell Transplantation 1Pharmaceutical Preparations 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Immunoglobulin Light-chain Amyloidosis × Cyclophosphamide × 90 days × Clear all
NCT06022939 2026-05-06

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

SWOG Cancer Research Network

Phase 3 Recruiting
338 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT04512235 2026-04-07

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
281 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
125 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT07224672 2026-03-17

ALANIS

GlaxoSmithKline

Phase 2 Not yet recruiting
60 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT06627309 2026-03-09

Rapid dFLC Response Predict CHR in AL Amyloidosis

Peking University People's Hospital

Recruiting
50 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡